Log in to save to my catalogue

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B):...

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B):...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2718124470

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundLocalised prostate cancer is commonly treated with external beam radiotherapy and moderate hypofractionation is non-inferior to longer schedules. Stereotactic body radiotherapy (SBRT) allows shorter treatment courses without impacting acute toxicity. We report 2-year toxicity findings from PACE-B, a randomised trial of conventional...

Alternative Titles

Full title

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2718124470

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2718124470

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(22)00517-4

How to access this item